Company Filing History:
Years Active: 2018-2019
Title: Mark Hellmich: Innovator in Cancer Therapy
Introduction
Mark Hellmich is a notable inventor based in Galveston, TX (US). He has made significant contributions to the field of cancer therapy through his innovative research and patents. With a focus on the use of hydrogen sulfide synthesis inhibitors, his work aims to provide new treatment options for patients suffering from various types of cancer.
Latest Patents
Mark Hellmich holds 2 patents that reflect his commitment to advancing cancer treatment. His latest patents include the following:
1. **Use of hydrogen sulfide synthesis inhibitors for cancer therapy** - This patent involves methods that comprise administering an inhibitor of hydrogen sulfide biosynthesis, a cystathionine-β-synthase (CBS) inhibitor, or a hydrogen sulfide neutralizing agent to patients with cancer associated with elevated production of hydrogen sulfide.
2. **Apigenin analogs, compositions, and methods related thereto** - This patent focuses on apigenin analogues or derivatives developed as CBS inhibitors. These derivatives are intended for use as anticancer or anti-inflammatory agents, with applications in treating various cancers and fibrosis.
Career Highlights
Mark Hellmich is affiliated with the University of Texas System, where he conducts his research and develops his innovative ideas. His work has the potential to impact the lives of many patients by providing new therapeutic options.
Collaborations
Mark collaborates with esteemed colleagues such as Jia Zhou and Csaba Szabo, enhancing the scope and depth of his research efforts.
Conclusion
Mark Hellmich is a dedicated inventor whose work in cancer therapy is paving the way for innovative treatment options. His patents reflect a deep commitment to improving patient outcomes through scientific research and collaboration.